Shi, Y., Han, X., Zhao, Q., Zheng, Y., Chen, J., Yu, X., . . . Hu, P. (2024, June). Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: An open-label, single-arm, multicenter, phase I study. Experimental Hematology & Oncology.
Chicago Style (17th ed.) CitationShi, Yuankai, et al. "Tunlametinib (HL-085) Plus Vemurafenib in Patients with Advanced BRAF V600-mutant Solid Tumors: An Open-label, Single-arm, Multicenter, Phase I Study." Experimental Hematology & Oncology Jun. 2024.
MLA (9th ed.) CitationShi, Yuankai, et al. "Tunlametinib (HL-085) Plus Vemurafenib in Patients with Advanced BRAF V600-mutant Solid Tumors: An Open-label, Single-arm, Multicenter, Phase I Study." Experimental Hematology & Oncology, Jun. 2024.
Warning: These citations may not always be 100% accurate.